Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
VN
Vanda Pharmaceuticals Inc.
VNDA
Mkt Cap
$243.9M
Volume
904.26K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
VN
VNDA
VN
Vanda Pharmaceuticals Inc.
VNDA
News
·
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Mkt Cap
$243.7M
Volume
904.25K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Insider
Filings
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback.
Zacks Investment Research · Oct 15, 2026
Stock Market Today: S&P 500, Dow Jones Futures Down As Santa Rally Hopes Fade—Investors Await Initial Jobless Claims Report
U.S. stock futures declined on New Year's Eve as hopes for a year-end Santa Claus rally fade. Markets remain jittery following President Trump's threats against Federal Reserve Chair Jerome Powell. Investors await the Initial Jobless Claims report before market open. The S&P 500, Dow Jones, and Nasdaq 100 all traded lower in premarket, with several individual stocks showing significant moves based on company announcements and FDA approvals.
Benzinga · Dec 31, 2025
Gastroparesis Market Poised for Extraordinary Growth at a 21.9% CAGR in the US by 2034 Due to the Launch of Novel MoAs Such as NK-1R Antagonists, 5-HT4 Receptor Agonists, D2 Receptor Antagonists, and Others | DelveInsight
The gastroparesis market is expected to grow significantly at a 21.9% CAGR by 2034, driven by novel therapeutic approaches targeting different receptor mechanisms and addressing current treatment limitations.
GlobeNewswire Inc. · Oct 27, 2025
Vanda (VNDA) Q2 Revenue Rises 4%
Vanda Pharmaceuticals reported a Q2 2025 net loss of $27.2 million, with revenue rising 4% to $52.6 million. Fanapt® showed strong sales growth, while HETLIOZ® and PONVORY® experienced declines. The company continues to invest in its product pipeline and expand market reach.
The Motley Fool · Aug 1, 2025
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight
The schizophrenia market is growing due to increased R&D activities, advancements in neurobiology and biomarkers, and ongoing clinical trials for more effective treatments. This has attracted significant investments and led to the development of innovative therapies, including novel antipsychotics and personalized medicine.
GlobeNewswire Inc. · Oct 9, 2024
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research · Jun 7, 2024
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.
Zacks Investment Research · May 16, 2024
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 2, 2024
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
Vanda Pharmaceuticals (VNDA) reachead $4.56 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.
Zacks Investment Research · Apr 24, 2024
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.
Zacks Investment Research · Apr 24, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
VN
VNDA
Vanda Pharmaceuticals Inc.
Buy
Sell
Market
Limit
Soon
VNDA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any VNDA yet.
Related Tickers
Earnings